Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Medexus Pharmaceuticals Inc (MDP.VN)

Medexus Pharmaceuticals Inc (MDP.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medexus Pharmaceuticals Inc 1 Place du Commerce Suite 225 Verdun QC H3E 1A2 CAN

P: 514-762-2626

Description:

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company. It is focused on auto-immune and pediatric diseases in the USA and Canada. The company's only reportable segment being the products sold and the marketing services offered to the pharmaceutical industry. Geographically, it derives a majority of revenue from the United States. Its product portfolio includes Rasuvo, Metoject, Rupall, Gliolan, and Treosulfan.

Key Statistics

Overview:

Market Capitalization, $K 146,241
Shares Outstanding, K 19,167
Annual Sales, $ 74,359 K
Annual Net Income, $ -6,236 K
Last Quarter Sales, $ 31,512 K
Last Quarter Net Income, $ -17,066 K
60-Month Beta 1.15
% of Institutional Shareholders 0.62%

Growth:

1-Year Return 171.93%
3-Year Return 18.77%
5-Year Return 233.33%
5-Year Revenue Growth 89.18%

Per-Share Information:

Most Recent Earnings -1.18 on 12/31/20
Next Earnings Date 06/28/21
Earnings Per Share ttm -1.80
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 12/19/18

MDP.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 192.31
Price/Earnings to Growth N/A
Return-on-Equity % -146.26%
Return-on-Assets % -18.07%
Profit Margin % -8.39
Net Margin % -0.24
Debt/Equity 7.79
Price/Sales 1.01
Price/Book 26.63
Book Value/Share 0.29
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar